MedPath

Skyepharma AG

🇧🇪Belgium
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

17

Active:7
Completed:9

Trial Phases

4 Phases

Early Phase 1:1
Phase 1:4
Phase 2:2
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials

Phase 3
6 (46.2%)
Phase 1
4 (30.8%)
Phase 2
2 (15.4%)
Early Phase 1
1 (7.7%)

The Gastric Residence Time (GRT) of Soctec Capsule After a Standardized Breakfast

Early Phase 1
Conditions
Healthy
First Posted Date
2015-01-09
Last Posted Date
2015-01-09
Lead Sponsor
SkyePharma AG
Target Recruit Count
15
Registration Number
NCT02335515

Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients

Phase 2
Completed
Conditions
Asthma
Interventions
First Posted Date
2009-01-27
Last Posted Date
2011-06-23
Lead Sponsor
SkyePharma AG
Target Recruit Count
64
Registration Number
NCT00830102
Locations
🇬🇧

Investigational site, Slough, United Kingdom

A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: SKP FlutiForm HFA pMDI
First Posted Date
2008-09-05
Last Posted Date
2011-06-23
Lead Sponsor
SkyePharma AG
Target Recruit Count
280
Registration Number
NCT00747318
Locations
🇲🇽

Investigational Site, Zapopan, Zapopan Jalisco, Mexico

🇺🇦

Investigational site, Zaporizhzhya, Ukraine

Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma

Phase 2
Completed
Conditions
Mild to Moderate Asthma
Interventions
First Posted Date
2008-08-14
Last Posted Date
2010-08-27
Lead Sponsor
SkyePharma AG
Target Recruit Count
39
Registration Number
NCT00734292
Locations
🇺🇸

Investigational Site, West Allis, Wisconsin, United States

A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands

Phase 1
Completed
Conditions
Asthma
Interventions
Drug: Oral Prednisone 10mg
Drug: Placebo
First Posted Date
2008-04-14
Last Posted Date
2008-12-01
Lead Sponsor
SkyePharma AG
Target Recruit Count
160
Registration Number
NCT00657774
Locations
🇺🇸

Investigational site, San Antonio, Texas, United States

🇺🇸

Investigational Site, Lake Oswego, Oregon, United States

  • Prev
  • 1
  • 2
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath